References
- Akkawi I, Zmerly H. Osteoporosis: current concepts. Joints. 2018;6:122–127.
- Weitzmann MN, Ofotokun I. Physiological and pathophysiological bone turnover - role of the immune system. Nat Rev Endocrinol. 2016;12:518–532.
- Marie PJ. Osteoblast dysfunctions in bone diseases: from cellular and molecular mechanisms to therapeutic strategies. Cell Mol Life Sci. 2015;72:1347–1361.
- van Wijnen AJ, van de Peppel J, van Leeuwen JP, et al. MicroRNA functions in osteogenesis and dysfunctions in osteoporosis. Curr Osteoporos Rep. 2013;11:72–82.
- Wang C, Lin K, Chang J, et al. Osteogenesis and angiogenesis induced by porous β-CaSiO(3)/PDLGA composite scaffold via activation of AMPK/ERK1/2 and PI3K/Akt pathways. Biomaterials. 2013;34:64–77.
- Zhong X, Xiu LL, Wei GH, et al. Bezafibrate enhances proliferation and differentiation of osteoblastic MC3T3-E1 cells via AMPK and eNOS activation. Acta Pharmacol Sin. 2011;32:591–600.
- Komori T. Runx2, an inducer of osteoblast and chondrocyte differentiation. Histochem Cell Biol. 2018;149:313–323.
- (a) Marie PJ, Kassem M. Osteoblasts in osteoporosis: past emerging and future anabolic targets. Eur J Endocrinol. 2011;165:1–10.; (b) Canalis E. New treatment modalities in osteoporosis. Endocr Pract. 2010;16:855–863.
- Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy. 2002;32:489–498.
- Akdis CA, Jutel M, Akdis M. Regulatory effects of histamine and histamine receptor expression in human allergic immune responses. Chem Immunol Allergy. 2008;94:67–82.
- Veglia E, Pini A, Moggio A, et al. Histamine type 1-receptor activation by low dose of histamine undermines human glomerular slit diaphragm integrity. Pharmacol Res. 2016;114:27–38.
- Okamoto T, Iwata S, Ohnuma K, et al. Histamine H1-receptor antagonists with immunomodulating activities: potential use for modulating T helper type 1 (Th1)/Th2 cytokine imbalance and inflammatory responses in allergic diseases. Clin Exp Immunol. 2009;157:27–34.
- Zhou Y, Gao C, Wang H, et al. Histamine H1 type receptor antagonist loratadine ameliorates oxidized LDL induced endothelial dysfunction. Biomed Pharmacother. 2018;106:1448–1453.
- Koç A, Elçin AE, Elçin YM. Ectopic osteogenic tissue formation by MC3T3-E1 cell-laden chitosan/hydroxyapatite composite scaffold. Artif Cells Nanomed Biotechnol. 2016;44:1440–1447.
- Sheng B, Wang X, Su B, et al. Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer’s disease. J Neurochem. 2012;120:419–429.
- Bhattarai G, Lee YH, Lee NH, et al. PPARγ delivered by Ch-GNPs onto titanium surfaces inhibits implant-induced inflammation and induces bone mineralization of MC-3T3E1 osteoblast-like cells. Clin Oral Impl Res. 2013;24:1101–1109.
- Kim JE, Takanche JS, Kim JS, et al. Phelligridin D-loaded oral nanotube titanium implant enhances osseointegration and prevents osteolysis in rat mandible. Artif Cells Nanomed Biotechnol. 2018;12:1–11.
- Sheng B, Gong K, Niu Y, et al. Inhibition of gamma-secretase activity reduces Abeta production, reduces oxidative stress, increases mitochondrial activity and leads to reduced vulnerability to apoptosis: Implications for the treatment of Alzheimer’s disease. Free Radic Biol Med. 2009;46:1362–1375.
- Pos Z, Wiener Z, Pocza P, et al. Histamine suppresses fibulin-5 and insulin-like growth factor-II receptor expression in melanoma. Cancer Res. 2008;68:1997–2005.
- Barbagallo I, Vanella A, Peterson SJ, et al. Overexpression of heme oxygenase-1 increases human osteoblast stem cell differentiation. J Bone Miner Metab. 2010;28:276–288.
- Li Z, Müller R, Ruffoni D. Bone remodeling and mechanobiology around implants: Insights from small animal imageing. J Orthop Res. 2018;36:584–593.
- Weitzmann MN. Bone and the immune System. Toxicol Pathol. 2017;45:911–924.
- Kim HM, Kim DH, Han HJ, et al. Ginsenoside Re promotes osteoblast differentiation in mouse osteoblast precursor MC3T3-E1 cells and a Zebrafish model. Molecules 2016;22:E42.
- Kodama H-a, Amagai Y, Sudo H, et al. Establishment of a clonal osteogenic cell line from newborn mouse calvaria. Jpn J Oral Biol. 1981;23:899–901.
- Vena GA, Cassano N, Buquicchio R, et al. Antiinflammatory effects of H1-antihistamines: clinical and immunological relevance. CPD. 2008;14:2902–2911.
- Liu X, Kumagai G, Wada K, et al. Suppression of osteogenic differentiation in mesenchymal stem cells from patients with ossification of the posterior longitudinal ligament by a histamine-2-receptor antagonist. Eur J Pharmacol. 2017;810:156–162.
- Valenti MT, Dalle Carbonare L, Mottes M. Osteogenic differentiation in healthy and pathological conditions. IJMS. 2016;18:41.
- Komori T. Roles of Runx2 in skeletal development. Adv Exp Med Biol. 2017;962:83–93.
- Fan X, Rahnert JA, Murphy TC, et al. Response to mechanical strain in an immortalized pre-osteoblast cell is dependent on ERK1/2. J Cell Physiol. 2006;207:454–460.
- Thors B, Halldórsson H, Thorgeirsson G. eNOS activation mediated by AMPK after stimulation of endothelial cells with histamine or thrombin is dependent on LKB1. Biochim Biophys Acta. 2011;1813:322–331.
- Jeyabalan J, Shah M, Viollet B, et al. AMP-activated protein kinase pathway and bone metabolism. J Endocrinol. 2012;212:277–290.